SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Vertex Pharmaceuticals Incorporated (VRTX) trades at a trailing P/E of 28.3, forward P/E of 23.0. Trailing earnings yield is 3.54%, forward earnings yield 4.34%. PEG 0.89 (Peter Lynch undervalued ≤1.0). Graham Number is $160.48.
Criteria proven by this page:
- VALUE (52/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 23.0 (down from trailing 28.3) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.89 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.54% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 4.34% as earnings recover.
- Analyst consensus target $549.73 (+23.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 84/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
52/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VRTX
Valuation Multiples
P/E (TTM)28.3
Forward P/E23.0
PEG Ratio0.89
Forward PEG0.89
P/B Ratio5.99
P/S Ratio9.29
EV/EBITDA22.9
Per Share Data
EPS (TTM)$15.57
Forward EPS (Est.)$19.30
Book Value / Share$73.52
Revenue / Share$47.41
FCF / Share$12.58
Yields & Fair Value
Earnings Yield3.54%
Forward Earnings Yield4.34%
Dividend Yield0.00%
Graham Number$160.48
SharesGrow IV$645.55 (+45.3%)
Analyst Target$549.73 (+23.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-160.2 |
2.00 |
15.52 |
10.54 |
- |
| 2017 |
141.5 |
-0.43 |
18.38 |
14.99 |
- |
| 2018 |
20.1 |
0.03 |
9.50 |
13.83 |
- |
| 2019 |
47.8 |
-1.07 |
9.24 |
13.50 |
- |
| 2020 |
22.6 |
0.18 |
7.07 |
9.90 |
- |
| 2021 |
24.2 |
-1.87 |
5.60 |
7.47 |
- |
| 2022 |
22.3 |
0.52 |
5.32 |
8.28 |
- |
| 2023 |
29.0 |
3.48 |
5.96 |
10.62 |
- |
| 2024 |
-193.6 |
1.69 |
6.32 |
9.41 |
- |
| 2025 |
29.3 |
-0.03 |
6.21 |
9.60 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.46 |
$1.7B |
$-112.05M |
-6.6% |
| 2017 |
$1.04 |
$2.49B |
$263.48M |
10.6% |
| 2018 |
$8.09 |
$3.05B |
$2.1B |
68.8% |
| 2019 |
$4.51 |
$4.16B |
$1.18B |
28.3% |
| 2020 |
$10.29 |
$6.21B |
$2.71B |
43.7% |
| 2021 |
$9.01 |
$7.57B |
$2.34B |
30.9% |
| 2022 |
$12.82 |
$8.93B |
$3.32B |
37.2% |
| 2023 |
$13.89 |
$9.87B |
$3.62B |
36.7% |
| 2024 |
$-2.08 |
$11.02B |
$-535.6M |
-4.9% |
| 2025 |
$15.32 |
$12.07B |
$3.95B |
32.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$19.32 |
$18.23 – $20.14 |
$13.03B |
$12.36B – $13.24B |
20 |
| 2027 |
$22.25 |
$20.54 – $24.15 |
$14.37B |
$13.44B – $16.46B |
18 |
| 2028 |
$25.20 |
$14.13 – $35.75 |
$15.99B |
$15.98B – $15.99B |
13 |
| 2029 |
$29.57 |
$27.31 – $32.79 |
$17.85B |
$16.8B – $19.34B |
11 |
| 2030 |
$33.61 |
$31.04 – $37.27 |
$19.79B |
$18.63B – $21.45B |
5 |
